Clinical e-audit for medicines in older people

NPS has developed a new clinical e-audit for GPs to review their medicines management of patients over the age of 75 who are on five or more medicines as well as an antipsychotic, benzodiazepine or opioid.

The online clinical audit is aimed at helping GPs to implement a systematic approach to review older patients' medicines and to assess risk factors in older people that may contribute to medicines-related problems or adverse events.

The medicines in older people clinical e-audit joins other currently available e-audits, including CVD risk and lipid-modifying therapy, type 2 diabetes: priorities and targets, and management of specific respiratory tract infections.

The new e-audit also aims to help GPs discuss the benefits of non-pharmacological therapies for older patients, to evaluate their response to medicines and to assess the need for ongoing therapy specifically for antipsychotic medicines for the behavioural and psychological symptoms of dementia, benzodiazepines for insomnia or opioids for chronic non-cancer pain.

Once 100 GPs have submitted their initial data, an expert commentary will be prepared by David Le Couteur, a professor of geriatric medicine at the University of Sydney's Concord Clinical School.

Accreditation for CPD points for the e-audits for the coming 2014–2016 triennium is pending. NPS applies for approval by the RACGP QI&CPD program and the ACRRM PD program.

The e-audits are recognised for the quality prescribing incentive (QPI) of the Practice Incentives Program (PIP).

Posters and patient leaflets to explain clinical audits and their privacy considerations are available from NPS.

Posted in Aged Care

You need to log in to post comments. If you don't have a Pulse+IT website account, click here to subscribe.

Sign up for Pulse+IT eNewsletters

Sign up for Pulse+IT website access

For more information, click here.

Copyright © 2021 Pulse+IT Communications Pty Ltd
No content published on this website can be reproduced by any person for any reason without the prior written permission of the publisher.
Supported by Social Media Agency | pepperit